Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review
Synovial sarcoma (SS) is an aggressive malignancy which accounts for approximately 5–10% of all soft-tissue sarcomas. SS has pathologic and genomic characteristics that define it as a distinct subtype of soft tissue sarcoma (STS). STS subtypes continue to be recognized as distinct entities with spec...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/10/11/417 |
| _version_ | 1797726216903458816 |
|---|---|
| author | Richard F. Riedel Robin L. Jones Antoine Italiano Chet Bohac Juliette C. Thompson Kerstin Mueller Zaeem Khan Seth M. Pollack Brian A. Van Tine |
| author_facet | Richard F. Riedel Robin L. Jones Antoine Italiano Chet Bohac Juliette C. Thompson Kerstin Mueller Zaeem Khan Seth M. Pollack Brian A. Van Tine |
| author_sort | Richard F. Riedel |
| collection | DOAJ |
| description | Synovial sarcoma (SS) is an aggressive malignancy which accounts for approximately 5–10% of all soft-tissue sarcomas. SS has pathologic and genomic characteristics that define it as a distinct subtype of soft tissue sarcoma (STS). STS subtypes continue to be recognized as distinct entities with specific characteristics, including differential chemo-sensitivity. The objective of this study was to conduct a descriptive review of current data on survival outcomes of systemic anti-cancer therapy specific to SS. A systematic literature review was conducted, using a custom search strategy to search EMBASE, Medline and CENTRAL for clinical trials and observational studies reporting overall survival (OS), progression-free survival (PFS) and/or response for cohorts of at least 50 SS patients. We identified 28 studies meeting these criteria, 25 of which were retrospective studies. Only three prospective studies were identified. Survival reports varied widely between studies based on the population, in particular on the disease stage, and reporting was heterogeneous in terms of the time points reported on. For patients with localized disease, reports of five-year PFS ranged from 26% to 80.7% and five-year OS from 40% to 90.7%, whereas five-year OS for patients with metastatic disease was very low at around 10%; and in one case, 0% was reported. Only four of the included publications reported outcomes by type of systemic anti-cancer therapy received. Our study draws attention to the fact that additional prospective studies to better define the most appropriate treatment for SS in all stages and lines of therapy are still needed. |
| first_indexed | 2024-03-12T10:42:34Z |
| format | Article |
| id | doaj.art-5491233715dd4e43b5260079ef82ed70 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T10:42:34Z |
| publishDate | 2018-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-5491233715dd4e43b5260079ef82ed702023-09-02T07:59:38ZengMDPI AGCancers2072-66942018-11-01101141710.3390/cancers10110417cancers10110417Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic ReviewRichard F. Riedel0Robin L. Jones1Antoine Italiano2Chet Bohac3Juliette C. Thompson4Kerstin Mueller5Zaeem Khan6Seth M. Pollack7Brian A. Van Tine8Duke Cancer Institute, Duke University Health System, Durham, NC 27710, USAThe Royal Marsden NHS Foundation Trust, Institute of Cancer Research, London SW3 6JJ, UKDepartment of Medical Oncology, Institute Bergonié, 33000 Bordeaux, FranceImmune Design Corporation, San Francisco, CA 94080, USAICON Epidemiology, ICON plc, Abingdon OX14 4RY, UKICON Epidemiology, ICON plc, Vancouver, BC V6B 1P1, CanadaICON Epidemiology, ICON plc, Vancouver, BC V6B 1P1, CanadaFred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USADivision of Medical Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USASynovial sarcoma (SS) is an aggressive malignancy which accounts for approximately 5–10% of all soft-tissue sarcomas. SS has pathologic and genomic characteristics that define it as a distinct subtype of soft tissue sarcoma (STS). STS subtypes continue to be recognized as distinct entities with specific characteristics, including differential chemo-sensitivity. The objective of this study was to conduct a descriptive review of current data on survival outcomes of systemic anti-cancer therapy specific to SS. A systematic literature review was conducted, using a custom search strategy to search EMBASE, Medline and CENTRAL for clinical trials and observational studies reporting overall survival (OS), progression-free survival (PFS) and/or response for cohorts of at least 50 SS patients. We identified 28 studies meeting these criteria, 25 of which were retrospective studies. Only three prospective studies were identified. Survival reports varied widely between studies based on the population, in particular on the disease stage, and reporting was heterogeneous in terms of the time points reported on. For patients with localized disease, reports of five-year PFS ranged from 26% to 80.7% and five-year OS from 40% to 90.7%, whereas five-year OS for patients with metastatic disease was very low at around 10%; and in one case, 0% was reported. Only four of the included publications reported outcomes by type of systemic anti-cancer therapy received. Our study draws attention to the fact that additional prospective studies to better define the most appropriate treatment for SS in all stages and lines of therapy are still needed.https://www.mdpi.com/2072-6694/10/11/417synovial sarcomasurvivalchemotherapysystemic anti-cancer therapysystematic review |
| spellingShingle | Richard F. Riedel Robin L. Jones Antoine Italiano Chet Bohac Juliette C. Thompson Kerstin Mueller Zaeem Khan Seth M. Pollack Brian A. Van Tine Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review Cancers synovial sarcoma survival chemotherapy systemic anti-cancer therapy systematic review |
| title | Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review |
| title_full | Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review |
| title_fullStr | Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review |
| title_full_unstemmed | Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review |
| title_short | Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review |
| title_sort | systemic anti cancer therapy in synovial sarcoma a systematic review |
| topic | synovial sarcoma survival chemotherapy systemic anti-cancer therapy systematic review |
| url | https://www.mdpi.com/2072-6694/10/11/417 |
| work_keys_str_mv | AT richardfriedel systemicanticancertherapyinsynovialsarcomaasystematicreview AT robinljones systemicanticancertherapyinsynovialsarcomaasystematicreview AT antoineitaliano systemicanticancertherapyinsynovialsarcomaasystematicreview AT chetbohac systemicanticancertherapyinsynovialsarcomaasystematicreview AT juliettecthompson systemicanticancertherapyinsynovialsarcomaasystematicreview AT kerstinmueller systemicanticancertherapyinsynovialsarcomaasystematicreview AT zaeemkhan systemicanticancertherapyinsynovialsarcomaasystematicreview AT sethmpollack systemicanticancertherapyinsynovialsarcomaasystematicreview AT brianavantine systemicanticancertherapyinsynovialsarcomaasystematicreview |